About Synthetica Ltd.

Synthetica makes private equity investment from its own private capital. Synthetica also offers commercial loans from many affiliated lenders.

We have developed unique programs that complement early stage equity capital with appropriate deployment of debt, with innovative programs designed specifically for the needs of high growth companies, such as accounts receivable, purchase order and contract finance facilities. Access to these debt programs can provide liquidity and needed growth capital without expending equity capital, at a time when smaller companies might not have reached the valuations necessary to make equity capital cost-effective.

Because of our volume we have relationships with hundreds of commercial lenders and match you with the programs that most suit the circumstances of your company.  We are not a bank and that translates into flexibility, expertise and speed

We also provide key strategic management consulting to help companies and entrepreneurs structure certain type of revenue growth initiatives that historically prove to be difficult for smaller companies.  These include internationalization of their business,  the scaling of distribution and M&A services designed to accelerate growth

We blend efficient capital deployment with strategic resources to help small companies become market leaders.  

Through an  extensive network of financial resources and our team's unique entrepreneurial abilities, we are able to offer you  financial, strategic and business development support not available elsewhere. Our focus is centered on building our portfolio companies' profits and creating long term value for equity holders.

Our unique finance solutions have enabled companies to take advantage of sales growth opportunities that are larger than they can finance internally. Our focus is not necessarily the balance sheet of the client company, but rather the underlying transaction and its economic and commercial viability. With our Purchase Order Financing, clients are no longer hindered by the lack of working capital to get deals done.

We are a privately funded, closely held entity with a strong financial foundation enabling us to react quickly to unique financing requests. We are an investment company not a bank, therefore we are not hindered by the regulations that restrict banks. We offer the speed and flexibility to get deals done.

Synthetica originates all its commercial loans  under the California Finance Lenders Law, Broker Lic. 603F700.  

Newest Virtual Road Shows

No groups yet...

Capital Markets News

  • Dicom Grid Raises $5M Expansion Round From Canaan, CHL Medical

    17 May 2012, 4:20 am
    Dicom Grid Inc., a provider of a cloud software-as-a-service platform for medical-imaging applications, said it has raised $5 million in Series 2 financing to expand distribution of a product line used to manage diagnostic-imaging and ...
  • Cardiac-Device Developer Mitralign Raises $35M Series D For European Clinical Trials

    17 May 2012, 3:46 am
    Mitralign Inc. said it has raised $35 million in a Series D round to fund studies that may enable it to gain European approval for a product designed to make a common heart-valve procedure less invasive.
  • Dicom Grid Raises $5M Expansion Round From Canaan, CHL Medical

    17 May 2012, 3:33 am
    Dicom Grid Inc., a provider of a cloud software-as-a-service platform for medical-imaging applications, said it has raised $5 million in Series 2 financing to expand distribution of a product line used to manage diagnostic-imaging and ...
  • Ra Pharma Closes $8.6M Series A Tranche, Makes Hereditary Angiodema Lead Program

    17 May 2012, 3:31 am
    Ra Pharmaceuticals Inc., which is developing a new class of peptide-like drugs known as Cyclomimetics, said it has secured an $8.6 million second tranche of a $27 million Series A round and has selected the rare condition hereditary ...
  • Roundup Of Form D Regulatory Filings

    17 May 2012, 3:28 am
    (The following is a roundup of selected companies that have revealed fund-raising activity in recent Form D regulatory filings. These companies are required to file a Form D notification within 15 days after the first sale of securities in ...